Close Menu

Phase III Begins

Phase III testing of Moderna's candidate SARS-CoV-2 vaccine has started today, NPR reports.

The trial will involve some 30,000 people, half of whom will receive two injections of the candidate vaccine, dubbed mRNA-1273, and half of whom will receive a saline placebo. Researchers will then monitor whether the vaccine can prevent those who receive it from becoming ill with COVID-19. 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

According to the Wall Street Journal, the Food and Drug Administration may soon issue an Emergency Use Authorization for convalescent plasma to treat COVID-19 patients.

Minnesota police have used genetic genealogy to make an arrest in a 1986 cold case, reports NBC News.

Researchers have used CRISPR-Cas9 to efficiently target a cephalopod pigmentation gene, as they report in Current Biology.

In Science this week: chromatin accessibility of microglia during fetal development, and more.